03914nas a2200277   4500000000100000008004100001100002200042700003100064700001500095700001700110700001500127700002500142700001800167700002200185700001700207700002000224700001800244700001400262700001900276700001800295245015800313300001100471490000800482520313200490022001403622       2013                            d1 aBompoint Severine1 aUMPIRE Collaborative Group1 aThom Simon1 aPoulter Neil1 aField Jane1 aPrabhakaran Dorairaj1 aStanton Alice1 aGrobbee Diederick1 aBots Michiel1 aK Reddy Srinath1 aCidambi Raghu1 aRodgers A1 aBillot Laurent1 aPatel Anushka00aEffects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.  a918-290 v3103 a<p>
<b>IMPORTANCE: </b>Most patients with cardiovascular disease (CVD) do not take recommended medications long-term. The use of fixed-dose combinations (FDCs) improves adherence in several clinical areas. Previous trials of cardiovascular FDCs have assessed short-term effects compared with placebo or no treatment.
</p>

<p>
<b>OBJECTIVE: </b>To assess whether FDC delivery of aspirin, statin, and 2 blood pressure-lowering agents vs usual care improves long-term adherence to indicated therapy and 2 major CVD risk factors, systolic blood pressure (SBP) and low-density lipoprotein cholesterol (LDL-C).
</p>

<p>
<b>DESIGN, SETTING, AND PARTICIPANTS: </b>The UMPIRE trial, a randomized, open-label, blinded-end-point trial among 2004 participants with established CVD or at risk of CVD enrolled July 2010-July 2011 in India and Europe. The trial follow-up concluded in July 2012.
</p>

<p>
<b>INTERVENTIONS: </b>Participants were randomly assigned (1:1) to an FDC-based strategy (n=1002) containing either (1) 75 mg aspirin, 40 mg simvastatin, 10 mg lisinopril, and 50 mg atenolol or (2) 75 mg aspirin, 40 mg simvastatin, 10 mg lisinopril, and 12.5 mg hydrochlorothiazide or to usual care (n=1002).
</p>

<p>
<b>MAIN OUTCOMES AND MEASURES: </b>Adherence to medication (defined as self-reported use of antiplatelet, statin, and ≥2 BP-lowering medications) and changes in SBP and LDL-C from baseline.
</p>

<p>
<b>RESULTS: </b>At baseline, mean BP was 137/78 mm Hg, LDL-C was 91.5 mg/dL, and 1233 (61.5%) of 2004 participants reported use of antiplatelet, statin, and 2 or more BP-lowering medications. Median follow-up was 15 months (interquartile range, 12-18 months). The FDC group had improved adherence vs usual care (86% vs 65%; relative risk [RR] of being adherent, 1.33; 95% CI, 1.26-1.41; P &lt; .001) with concurrent reductions in SBP (-2.6 mm Hg; 95% CI, -4.0 to -1.1 mm Hg; P &lt; .001) and LDL-C (-4.2 mg/dL; 95% CI, -6.6 to -1.9 mg/dL; P &lt; .001) at the end of the study. Although there was consistency of effects across predefined subgroups, evidence existed of larger benefits in patients with lower adherence at baseline. In this subgroup of 727 participants (36%), adherence at the end of study was 77% vs 23% (RR, 3.35; 95% CI, 2.74-4.09; P &lt; .001 for interaction), SBP was reduced by 4.9 mm Hg (95% CI 7.3-2.6 mm Hg; P = .01 for interaction), and LDL-C was reduced by 6.7 mg/dL (95% CI, 10.5-2.8 mg/dL; P = .11 for interaction). There were no significant differences in serious adverse events or cardiovascular events (50 [5%] in the FDC group and 35 [3.5%] in the usual care group; RR, 1.45; 95% CI, 0.94-2.24; P=.09) between the groups.
</p>

<p>
<b>CONCLUSIONS AND RELEVANCE: </b>Among patients with or at high risk of CVD, use of an FDC strategy for blood pressure, cholesterol, and platelet control vs usual care resulted in significantly improved medication adherence at 15 months and statistically significant but small improvements in SBP and LDL-C.
</p>

<p>
<b>TRIAL REGISTRATION: </b>clinicaltrials.gov Identifier: NCT01057537.
</p>
  a1538-3598